An intervention to control an ICU outbreak of carbapenem-resistant Acinetobacter baumannii: long-term impact for the ICU and hospital
- PMID: 30463589
- PMCID: PMC6249923
- DOI: 10.1186/s13054-018-2247-y
An intervention to control an ICU outbreak of carbapenem-resistant Acinetobacter baumannii: long-term impact for the ICU and hospital
Abstract
Background: Following a fatal intensive care unit (ICU) outbreak of carbapenem-resistant Acinetobacter baumanii (CRAB) in 2015, an aggressive infection control intervention was instituted. We outline the intervention and long-term changes in the incidence and prevalence of CRAB.
Methods: The infection control intervention included unit closure (3 days), environmental cleaning, hand hygiene interventions, and environmental culturing. CRAB acquisition and prevalence and colistin use were compared for the 1 year before and 2 years after the intervention.
Results: Following the intervention, ICU CRAB acquisition decreased significantly from 54.6 (preintervention) to 1.9 (year 1) to 5.6 cases (year 2)/1000 admissions (p < 0.01 for comparisons with preintervention period.). Unexpectedly, ICU CRAB admission prevalence also decreased from 56.5 to 5.8 to 13 cases/1000 admissions (p < 0.001) despite the infection control intervention's being directed at the ICU alone. In parallel, hospital CRAB prevalence decreased from 4.4 to 2.4 to 2.5 cases/1000 admissions (p < 0.001), possibly as a result of decreased discharge of CRAB carriers from the ICU to the wards (58.5 to 1.9 to 7.4 cases/1000 admissions; p < 0.001). ICU colistin consumption decreased from 200 to 132 to 75 defined daily dose (DDD)/1000 patient-days (p < 0.05). Hospital colistin consumption decreased from 21.2 to 19.4 to 14.1 DDD/1000 patient-days (p < 0.05).
Conclusions: The ICU infection control intervention was highly effective, long-lasting, and associated with a decrease in last-line antibiotic use. The intervention was associated with the unexpected finding that hospital CRAB prevalence also decreased.
Keywords: Acinetobacter baumannii; ICU; Infection control; Outbreak.
Conflict of interest statement
Ethics approval and consent to participate
Information on ethics approval and consent is included in “Methods” section.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
Similar articles
-
A five-component infection control bundle to permanently eliminate a carbapenem-resistant Acinetobacter baumannii spreading in an intensive care unit.Antimicrob Resist Infect Control. 2021 Aug 19;10(1):123. doi: 10.1186/s13756-021-00990-z. Antimicrob Resist Infect Control. 2021. PMID: 34412693 Free PMC article.
-
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15. Microb Pathog. 2019. PMID: 30562602
-
Emergence of colistin and carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (CCR-Acb) complex in a neurological intensive care unit followed by successful control of the outbreak.J Infect Public Health. 2020 Apr;13(4):564-570. doi: 10.1016/j.jiph.2019.09.013. Epub 2019 Oct 29. J Infect Public Health. 2020. PMID: 31672426
-
The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature.Antimicrob Resist Infect Control. 2022 Jan 21;11(1):12. doi: 10.1186/s13756-022-01052-8. Antimicrob Resist Infect Control. 2022. PMID: 35063032 Free PMC article. Review.
-
Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter baumannii (CRAB) from Endemic Hospitals?Antibiotics (Basel). 2022 Jul 28;11(8):1015. doi: 10.3390/antibiotics11081015. Antibiotics (Basel). 2022. PMID: 36009885 Free PMC article. Review.
Cited by
-
Complex Infection-Control Measures with Disinfectant Switch Help the Successful Early Control of Carbapenem-Resistant Acinetobacter baumannii Outbreak in Intensive Care Unit.Antibiotics (Basel). 2024 Sep 11;13(9):869. doi: 10.3390/antibiotics13090869. Antibiotics (Basel). 2024. PMID: 39335042 Free PMC article.
-
Phenotypic and Molecular Characterization of Hypervirulent and Multidrug-Resistant Acinetobacter baumannii Isolated from ICU Respiratory Infections.Can J Infect Dis Med Microbiol. 2024 Sep 18;2024:9670708. doi: 10.1155/2024/9670708. eCollection 2024. Can J Infect Dis Med Microbiol. 2024. PMID: 39329052 Free PMC article.
-
Molecular epidemiology, microbiological features and infection control strategies for carbapenem-resistant Acinetobacter baumannii in a German burn and plastic surgery center (2020-2022).Antimicrob Resist Infect Control. 2024 Sep 6;13(1):99. doi: 10.1186/s13756-024-01459-5. Antimicrob Resist Infect Control. 2024. PMID: 39242542 Free PMC article.
-
Infection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria and Candida auris in Intensive Care Units: A Pragmatic Resume including Pathogens R0 and a Cost-Effectiveness Analysis.Antibiotics (Basel). 2024 Aug 22;13(8):789. doi: 10.3390/antibiotics13080789. Antibiotics (Basel). 2024. PMID: 39200090 Free PMC article. Review.
-
Study of MIC of silver and zinc oxide nanoparticles, strong and cost-effective antibacterial against biofilm-producing Acinetobacter baumannii in Shiraz, Southwest of Iran.BMC Infect Dis. 2024 Jun 17;24(1):593. doi: 10.1186/s12879-024-09471-1. BMC Infect Dis. 2024. PMID: 38886629 Free PMC article.
References
-
- Kohlenberg A, Brummer S, Higgins PG, Sohr D, Piening BC, de Grahl C, Halle E, Ruden H, Seifert H. Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre. J Med Microbiol. 2009;58(Pt 11):1499–1507. doi: 10.1099/jmm.0.012302-0. - DOI - PubMed
-
- Garlantezec R, Bourigault C, Boles JM, Prat G, Baron R, Tonnelier JM, Cosse M, Lefevre M, Jourdain S, Lelay G, et al. Cost-analysis of an intensive care unit closure due to an imipenem-resistant oxa-23 Acinetobacter baumannii outbreak. J Hosp Infect. 2011;77(2):174–175. doi: 10.1016/j.jhin.2010.09.027. - DOI - PubMed
-
- Ayraud-Thevenot S, Huart C, Mimoz O, Taouqi M, Laland C, Bousseau A, Castel O. Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure. J Hosp Infect. 2012;82(4):290–292. doi: 10.1016/j.jhin.2012.08.016. - DOI - PubMed
-
- Molter G, Seifert H, Mandraka F, Kasper G, Weidmann B, Hornei B, Ohler M, Schwimmbeck P, Kroschel P, Higgins PG, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii in the intensive care unit: a multi-level strategic management approach. J Hosp Infect. 2016;92(2):194–198. doi: 10.1016/j.jhin.2015.11.007. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials

